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The phospholipid mediator AGEPC (acetyl glyceryl ether phosphorylcholine) was examined for its effects 
on guinea pig peritoneal macrophages. At a concentration of 10-9-10-6 M, AGEPC evoked release of 
prostaglandin E (PGE) and thromboxane BZ (TXB2) from albumin-elicited macrophages. It also triggerd 
generation of 02 by Corynebacterium patvum-induced cells. Moreover, it caused augmented spreading of 
macrophages. The calmodulin antagonist W-7 attenuated AGEPC-mediated 0; production and cell 
spreading whereas prostanoid synthesis was enhanced. These novel actions of AGEPC on the major 
cellular component of the inflammatory process attest to its role as a potent mediator of 
immunoinflammatory responses. 
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1. INTRODUCTION 
Acetyl glyceryl ether phoshorylcholine 
(AGEPC, platelet-activating factor) is a phospho- 
lipid mediator originating from basophils, plate- 
lets, neutrophils, monocytes, and macrophages 
(mq5) that causes platelet activation, aggregation 
and degranulation of neutrophils, hypotension and 
bronchoconstriction and has been implicated in 
anaphylactic shock [1,2]. We have recently shown 
that AGEPC triggers in peritoneal rnq5 a burst of 
luminol-dependent chemiluminescence and release 
of Hz02 [3]. To characterize in more detail rnq5 ac- 
tivation mediated by AGEPC we examined its ef- 
fect on the conversion of arachidonic acid (AA) to 
prostaglandin E (PGE) and thromboxane B2 
(TXBz), the release of superoxide anion (02) 
generated in the oxidative burst, and on the 
spreading behavior of mq5, all responses represen- 
ting sensitive markers of augmented rnq5 function 
[4,5]. Furthermore, in view of the role attributed 
to calcium fluxes in activation processes of phago- 
cytic cells and their presumed dependence on 
calmodulin [6-lo], we investigated how the 
calmodulin inhibitor W-7 (N-(6-aminohexyl)-5- 
chloro-1-naphthalenesulfonamide) [l l] would af- 
fect AGEPC-dependent rnq5 responses. 
2. MATERIALS AND METHODS 
C 18 analog of AGEPC (l-0-octadecyl-2-acetyl- 
sn-glycero-3-phosphorylcholine) was purchased 
from Bachem (Bubendorf), W-7 from Paesel 
(Frankfurt). Hartley guinea pigs were injected i.p. 
with human serum albumin (HSA) or Cory- 
nebacterium parvum (C.p.) 4 or 14 days before 
sacrifice, respectively [ 12,131. Monolayers of rn4 
were established as described and consisted of 
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91-95% rnq5 as evidenced by non-specific esterase 
staining and latex phagocytosis, and were free of 
platelets as revealed by phase contrast microscopy 
[ 12,131. PGE and TXB2 in cell-free culture super- 
nates were determined by radioimmunoassay as in 
[ 12,131. Release of 02 was measured by cyto- 
chrome c reduction [ 131. PGE/TXBz synthesis was 
studied in HSA-elicited rnd, 02 generation in 
C.p.-elicited m4, since these rn4 populations have 
been shown to be most suitable for the respective 
studies [12-141. Spreading of rn@ on surfaces of 
culture wells (Cluster 6, Costar, Cambridge) was 
assayed as in [5,15] and results are expressed as % 
cells spread using criteria outlined in [5,15]. Cell 
viability was assessed by measuring release of the 
cytoplasmic enzyme lactate dehydrogenase (LDH) 
which for concentrations of AGEPC up to 10e6 M 
and W-7 up to 3 x 10e5 M did not exceed 10% of 
cellular content and was no different from values 
obtained in control incubates. 
3. RESULTS 
AGEPC evoked a dose-responsive release of 
PGE and TXB2 from HSA-elicited rnd at 
10T9- 1 0e6 M which could be completely abolished 
by addition of the cyclooxygenase inhibitor in- 
domethacin (0.5 pg/ml) (fig. 1A). Kinetic analysis 
revealed that PGE production proceeded at an 
tone AGEPC (-IogM) 
Fig.1. (A) Stimulation of PGE/TXB2 release. HSA- 
elicited mq5 were challenged with AGEPC. PGE/TXBz 
release was determined after 3 h. Results corrected for 
cell number by gauging DNA content of monolayers 
[3,12,13] are given per lo6 mq5 and represent means + 
SD of 5 experiments. Circles: PGE; triangles: TXB2. (B) 
Kinetics of PGE release. HSA-me4 were exposed to 
AGEPC (lo-’ M), and PGE-release was measured at 
indicated intervals. Results given per IO6 rnd, means f 
- cent W-7 l/M) ___) 
Fig.2. Influence of W-7. 2 min before challenge with 
AGEPC (lo-’ M) rnd were exposed to various doses of 
W-7. Or release from C.p. rn4 was determined at 
30 min, spreading was assessed at 4 h. Results expressed 
as % of controls exposed to AGEPC (lo-’ M) only. 
SD of 4 experiments with duplicate cultures. Means of 5 experiments. 
almost constant rate for 3 h when a plateau was 
reached (fig. 1B). A similar time course was observ- 
ed for TXBz liberation (not shown). 02 formation 
by C.p. rnqj was likewise stimulated at 
10-8-10-6 M. Kinetics followed the same time 
course as found for Hz02 [3] (not shown). Examin- 
ing its effects on rn4 spreading AGEPC was 
observed to increase the percentage of cells cover- 
ing a larger surface on culture wells (table 1). Prin- 
cipally, similar results were obtained in Cp. rn4 
except that, due to a higher number of untreated 
cells spread, increments were smaller (not shown). 
W-7 added to rnd at various doses 2 min before 
challenge with AGEPC, diminished both 02 
generation and spreading (fig.2). Sensitivity of 
these stimulating effects of AGEPC toward W-7 
was slightly different as is apparent from 
dose-response curves depicted in fig.2. In con- 
trast, liberation of PGE and TXBz was not 
adversely affected by W-7 but rather enhanced in 
its presence. AGEPC-stimulated PGE synthesis 
for example, was increased by 17 f 4131 f 7% in 
the presence of 10/20/1M W-7, respectively, as 
compared to production induced by AGEPC 
(lo-’ M) alone (means f SD of 4 expt). W-7 ef- 
fects at these concentrations were non-toxic as in- 
dicated by unchanged LDH release from rnd as 
compared to controls. Above 25 pM however, W-7 
was found to impair viability of rn$ as judged by 
enhanced leakage of LDH. 
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Table 1 
Effect of AGEPC on 02 production and spreading 
of me5 
[AGEPC] (M) 02 (nmol/106 m& % Cells spread 
1o-9 1.6 f 0.4 22* 5 
1o-8 6.9 f 1.3 39+ I 
lo-’ 13.6 f 2.4 51* 9 
1o-6 19.9 + 3.2 67 f 10 
Control 1.5 * 0.3 17+ 4 
Ot release from C.p.-elicited n@ was determined 30 min 
after addition of AGEPC, spreading of HSA-rnc5 was 
assessed 4 h after challenge with AGEPC. Control: me5 
incubated in medium. Means f SD of 6 expt with 
triplicate cultures 
4. DISCUSSION 
These findings indicate that AGEPC causes pro- 
found changes in the functional status of rnr$. 
Enhanced metabolic activity of mq5 as evidenced by 
production of AA cyclooxygenation products PGE 
and TXBz, 01, and augmentation of spreading are 
novel effects of AGEPC. PGE and TXBz are 
known to display phlogistic properties [12,13]. 02 
and derived reactive oxygen species have been in- 
voked in m&mediated microbial killing, cytotox- 
icity, destruction of endothelium and tissues [ 161. 
Considering these effects, our results further attest 
to the emerging stature of AGEPC as a potent 
mediator of immunoinflammatory responses. Two 
responses to AGEPC are reduced in magnitude to 
a variable degree by W-7. Much evidence has been 
advanced that calcium is pivotal in initiating ox- 
idative burst, phagocytosis and lysosomal enzyme 
release in neutrophils and mq5 [6-lo]. Moreover, 
the presence of calmodulin in mq5 has recently been 
demonstrated [9]. Taken together, the observed ef- 
fects of W-7 on AGEPC-mediated mq5 responses, 
at concentrations similar to those found to sup- 
press degranulation and 02 release from neutro- 
phils [ 17,181, could be explained by its calmodulin- 
inhibiting properties although unspecific hydro- 
phobic interactions cannot be totally excluded 
[19]. Assuming that W-7 acts by virtue of calmo- 
dulin antagonism, several sites of action are con- 
ceivable. With regard to prostanoid synthesis 
phospholipase AZ and C have been invoked as rate- 
limiting steps in AA metabolism of phagocytes 
although recent evidence suggests that phospholip- 
ase C and phosphatidylinositol breakdown are 
more important in providing free AA for conver- 
sion to eicosanoids [20-231. Enhanced production 
of PGE and TXBz in response to the joint action 
of AGEPC and W-7 is consistent with the demon- 
stration that phenothiazine calmodulin-inhibitors 
liberate AA from mq5 possibly through activation 
of diacylglycerol lipase 1231. In platelets phos- 
pholipase C-mediated events have been found to 
be stimulated by calmodulin-antagonists [24]. 
Diminution of 02 generation by W-7 is in accord 
with findings in neutrophils [17,18] and presum- 
ably the result of interacting with NADPH-oxi- 
dase. Cell-spreading is a calcium-dependent pro- 
cess [25], and trifluoperazine has been demon- 
strated to reduce spreading of cultured epithelial 
cells and fibroblasts [26]. In conclusion, AGEPC 
causes rnq5 activation and production of proinflam- 
matory compounds. These findings demonstrate 
important interactions between the phospholipid 
mediator AGEPC and the major cellular compo- 
nent of the inflammatory process. 
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